Nutraceutical Supplementation in Obese Patients and Effects on Anthropometric, Metabolic, and Inflammatory Parameters

Giuseppe Derosa^{1, 2,} , Angela D’Angelo³ and Pamela Maffioli¹

¹Centre of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

²Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy;Centre for Prevention, Surveillance, Diagnosis and Treatment of Dyslipidemia and Atherosclerosis, Fondazione IRCCS Policlinico San Matteo, PAVIA, Italy

³Laboratory of Molecular Medicine, University of Pavia, PAVIA, Italy

Cite this paper:
Giuseppe Derosa, Angela D’Angelo and Pamela Maffioli. Nutraceutical Supplementation in Obese Patients and Effects on Anthropometric, Metabolic, and Inflammatory Parameters. Journal of Food and Nutrition Research. 2023; 11(5):353-359. doi: 10.12691/jfnr-11-5-3

Abstract

The aim of this study was to evaluate if Metabolic® Ultra, a nutraceutical containing Chitosan and α-Lipoic acid (Nutraceutical), can decrease anthropometric measures and ameliorate metabolic values, inflammatory status, and cytokine parameters in patients with obesity. We enrolled 60 Caucasian obese (BMI ≥ 30 kg/m²) nondiabetic patients, aged ≥ 18 of either sex. Patients were randomized to take placebo or Nutraceutical for 6 months, in a randomized, double-blind, placebo-controlled design. Nutraceutical and placebo were self-administered twice a day, 3 tablets fifteen minutes before lunch and dinner. A significant decrease of weight, BMI, and Abd. Cir. were observed after 6 months of Nutraceutical treatment (p< 0.05 vs Baseline) compared to placebo. No Waist Cir. and Hip Cir. variations were observed in both groups. No variation of FPG, FPI, and Homa index were recorded in both groups compared to Baseline. A significant TC, LDL-C, and Tg decrease was recorded at 6 months in the Nutraceutical group compared to the placebo group (p< 0.05 vs Baseline, respectively), and a significant TC, and LDL-C decrease was found at 6 months compared to placebo group (p< 0.05, respectively). No significant HDL-C variation was observed in the Nutraceutical group, although there was an increasing trend. High-sensitivity C-reactive protein was significantly reduced at 6 months in the Nutraceutical group (p< 0.05 vs Baseline, and p< 0.05 vs placebo), while the ADN was raised to 6 months in the Nutraceutical group (p< 0.05 vs Baseline, and p< 0.05 vs placebo). No significant change was seen for IL-6 and TNF-α at the end of the study in both treatments. All the patients who finished the study and underwent OGTT at Baseline and after 6 months were euglycemic at the end of the second hour in both groups. We can conclude that a nutraceutical containing Chitosan and α-Lipoic acid can be helpful in reducing weight and BMI, in improving lipid profile, and in reducing inflammatory parameters, without affecting the glycemic status of obese patients.

Keywords:
α-Lipoic acid inflammation obesity chitosan

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Crandall DL, Hausman GJ, Kral JG. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Microcirculation 1997; 4: 211-232.
[2]	Ailhaud G, Grimaldi P, Ne’grel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr 1992; 12: 207-233.
[3]	Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
[4]	Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008; 57(11): 1552-1557.
[5]	Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med 2010; 49 (16): 1717-1725.
[6]	Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. J Pharm Pharm Sci 2010; 13(3): 378-390.
[7]	Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF. Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism 2011; 60: 421-429.
[8]	Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. J Clin Pharm Ther 2011; 36(5): 592-601.
[9]	Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J 2010; 57(9): 777-786.
[10]	Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother 2010; 11(12): 1971-1982.
[11]	Derosa G, Cicero AFG, D’Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012; 37(2): 187-195.
[12]	Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF. Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol 2011; 25(5): 642-651.
[13]	James WPT, Caterson ID, Coutinho W, et al. for the SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
[14]	http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm.
[15]	Ríos-Hoyo A, Gutiérrez-Salmeán G. New dietary supplements for obesity: what we currently know. Curr Obes Rep 2016; 5: 262–270.
[16]	Lütjohann D, Marinova M, Wolter K, et al. Influence of chitosan treatment on surrogate serum markers of cholesterol metabolism in obese subjects. Nutrients 2018; 10: 1-16.
[17]	Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 2006; 26: 2186-2191.
[18]	European Diabetes Policy Group desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
[19]	Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
[20]	Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
[21]	Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem 1978; 15: 121-130.
[22]	Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Methods of Enzymatic Analysis. Ed. H. U. Bergmeyer, 2nd English ed. Academic Press, New York (USA) 1974; pp. 18-31.
[23]	Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-1353.
[24]	Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
[25]	Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001; 7: 941-946.
[26]	Song M, Kellum JA. Interleukin-6. Crit. Care Med 2005; 33(12), S463-S465.
[27]	Zhang M, Tracey K. The Cytokine Handbook 1988, 3rd ed. San Diego: Academic Press.
[28]	Rifai N, Tracy RP, Ridker PM. Clinical Efficacy of an Automated High-Sensitivity C-Reactive Protein Assay. Clin Chem 1999; 45(12): 2136-2141.
[29]	American Diabetes Association 2019. Standards of Medical Care in Diabetes. Diabetes Care 2019; 42(Suppl 1): S184-S186.
[30]	Winer BJ. Statistical Principles in Experimental Design. 2nd ed., McGraw-Hill, New York (USA) 1971.
[31]	Hernández-González SO, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA. Chitosan improves insulin sensitivity as determined by the euglycemic-hyperinsulinemic clamp technique in obese subjects. Nutr Res 2010; 30 (6): 392-395.
[32]	Trivedi VR, Satia MC, Deschamps A, Maquet V, Shah RB, Zinzuwadia PH, Trivedi JV. Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction. Nutr J 2016; 15: 3.
[33]	Lütjohann D, Marinova M, Wolter K, Willinek W, Bitterlich N, Coenen M, Coch C, Stellaard F. Influence of Chitosan Treatment on Surrogate Serum Markers of Cholesterol Metabolism in Obese Subjects. Nutrients 2018;10: 72.
[34]	Mhurchu CN, Poppitt SD, McGill AT, Leahy FE, Bennett DA, Lin RB, Ormrod D, Ward L, Strik C, Rodgers A. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord 2004; 28(9): 1149-1156.
[35]	Hayashi K, Ito M. Antidiabetic action of low molecular weight chitosan in genetically obese diabetic KK-Ay mice. Biol Pharm Bull 2002; 25 (2):188-192.
[36]	Kim JG, Jo SH, Ha KS, Kim SC, Kim YC, Apostolidis E, Kwon YI. Effect of long-term supplementation of low molecular weight chitosan oligosaccharide (GO2KA1) on fasting blood glucose and HbA1c in db/db mice model and elucidation of mechanism of action. BMC Complement Altern Med 2014; 14: 272.
[37]	Walsh AM, Sweeney T, Bahar B, O'Doherty JV. Multi-functional roles of chitosan as a potential protective agent against obesity. PLoS One 2013; 8(1): e53828.
[38]	Lee SH, Senevirathne M, Ahn CB, Kim SK, Je JY. Factors affecting anti-inflammatory effect of chitooligosaccharides in lipopolysaccharides-induced RAW264.7 macrophage cells. Bioorg Med Chem Lett 2009; 19(23): 6655-6658.
[39]	Kim HM, Hong SH, Yoo SJ, Baek KS, Jeon YJ, Choung SY. Differential effects of chitooligosaccharides on serum cytokine levels in aged subjects. J Med Food 2006; 9(3): 427-430.